Details of Drug-Drug Interaction
| Drug General Information (ID: DDI07B1WEK) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Iloprost | Drug Info | Deoxycholic acid | Drug Info | |||||
| Drug Type | Small molecule | Small molecule | |||||||
| Therapeutic Class | Antihypertensive Agents | Cytolytic Agents | |||||||
| Structure | |||||||||
| Mechanism of Iloprost-Deoxycholic acid Interaction (Severity Level: Moderate) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Increased risk of bleeding Click to Show/Hide Mechanism Graph | |||||||||
![]() |
|||||||||
| Drug Name | Iloprost | Deoxycholic acid | |||||||
| Mechanism |
Risk of bleeding Thrombolytic agent |
Risk of submental hematoma or bruising | |||||||
| Key Mechanism Factor 1 | |||||||||
| Factor Name | Bleeding | ||||||||
| Factor Description | Patients may be at risk for bleeding when the outcome of a disease or disease treatment confounds the standard mechanisms for maintaining hemostasis. Signs or symptoms of abnormal bleeding include: bleeding that takes a long time to stop (including nosebleeds, bleeding gums, bleeding from cuts and abrasions, and menstrual bleeding); severe unexplained bruising, or bruising that becomes larger; blood in the urine or stool, etc. | ||||||||
| Mechanism Description |
|
||||||||
| Recommended Action | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Management | Deoxycholic acid should be used with caution in patients receiving drugs that may interfere with hemostasis. | ||||||||
| References | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Product Information. Brukinsa (zanubrutinib). BeiGene USA, Inc, San Mateo, CA. | ||||||||||||||||||
| 2 | Product Information. Kybella (deoxycholic acid). Kythera Biopharmaceuticals, Inc., Westlake Village, CA. | ||||||||||||||||||

